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viruses could potentially induce systemic antitumor effects, or
the abscopal effect, as they self-amplify in tumors, induce
danger signaling, and promote tumor-associated antigen pre-
sentation. In this study, oncolytic adenovirus coding for hu-
man tumor necrosis factor alpha (TNF-a) and interleukin-2
(IL-2) Ad5/3-E2F-d24-hTNF-a-IRES-hIL-2 (also known as
[a.k.a.] TILT-123) provoked antitumor efﬁcacy in tumors
that were injected with Ad5/3-E2F-d24-hTNF-a-IRES-hIL-2
and those that were left non-injected in the same animal.
Importantly, the virus was able to travel to distant tumors.
To dissect the effects of oncolysis and cytokines, we studied
replication-incompetent viruses in mice. Systemic antitumor
effects were similar in both models, highlighting the impor-
tance of the arming device. The cytokines induced positive
changes in immune cell inﬁltrates and induced the expression
of several immune-reaction-related genes in tumors. In addi-
tion, Ad5/3-E2F-d24-hTNF-a-IRES-hIL-2 was able to increase
homing of adoptively transferred tumor-inﬁltrating lympho-
cytes into both injected and non-injected tumors, possibly
mediated through chemokine expression. In summary, local
treatment with Ad5/3-E2F-d24-hTNF-a-IRES-hIL-2 resulted
in systemic antitumor efﬁcacy by inducing immune cell inﬁl-
tration and trafﬁcking into both treated and untreated tumors.
Moreover, the oncolytic adenovirus platform had superior
systemic effects over replication-deﬁcient vector through
spreading into distant tumors.Received 31 October 2018; accepted 31 October 2018;
https://doi.org/10.1016/j.omto.2018.10.005.
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Eight million cancer deaths occur globally each year, and almost all of
them result from metastatic cancer.1 New therapeutic approaches are
thus urgently needed. Because the patients in need of novel treat-
ments typically have metastatic disease, systemic therapeutic efﬁcacy
is required. After a century of developing immunotherapies, the ﬁrst
products have recently entered routine use. Many of them, including
monoclonal checkpoint blocking antibodies and recombinant cyto-
kines, are used systemically, which can cause severe adverse events
and even mortality by affecting normal tissues.2,3 In contrast, theMolecular Th
This is an open access article under the CC BY-NC-typical embodiment of oncolytic immunotherapy is a local injection
into tumors. Several types of oncolytic viruses are being investigated
in preclinical and clinical studies, and one product, talimogene laher-
parepvec (also known as [a.k.a.] T-Vec or Imlygic), has already been
approved.4–6 Even though T-Vec is not capable of spreading to
distant tumors, local injection causes immunological reactions in
distant metastases, a phenomenon known as abscopal effect.6,7
The abscopal effect has been proposed as potentially relevant in
patients being treated with systemic immunotherapy, such as check-
point blocking antibodies, and local radiation.8,9 The biological ratio-
nale is that radiation can cause immunogenic cell death, allowing the
induction of new T cells against the tumor, while concurrent check-
point inhibitors prevent immunosuppression from occurring. This
approach is now being tested in dozens of trials.10 Oncolytic viruses,
such as T-Vec, are able to induce an abscopal effect without the need
for radiation.6,7 The biological rationale is the same: oncolytic replica-
tion can induce immunogenic cell death and immunological danger
signaling, both of which can induce de novo immunity against the
tumor.
With regard to oncolytic viruses under development, but not yet
approved (except oncolytic adenovirus Oncorine in China), oncolytic
adenoviruses are well tolerated in humans and excellent devices for
transgene delivery.5,11,12 For example, toxic systemic delivery of IL-2,
regularly used in adoptive cell therapy protocols, is replaceable with
virus-vectored IL-2 gene therapy in the context of T cell transfer.13
In addition to immune stimulation by the transgene, adenoviral oncol-
ysis induces immunogenic cell death and the release of danger signals
and tumor-associated antigens, which increase tumor immunoge-
nicity.14–16 Importantly, adenovirally delivered cytokines provide
enhanced antitumor efﬁcacywithminimal or nonexistent toxicity.13,17erapy: Oncolytics Vol. 11 December 2018 ª 2018 The Authors. 109
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Treatment with Oncolytic Virus Controls the Growth of Both Injected and Non-injected Tumors
Hamsters were treated on days 1, 8, 15, 22, and 29 with 1 108 VPs intratumorally (i.t.) and with 5 107 TILs on day 1 intraperitoneally (i.p.). The growth of injected (A) and
non-injected (B) hamster tumors (n = 5–6) was measured every 2–3 days until day 33. During the follow-up period, two animals were sacrificed from themock group (day 24),
two animals from the group receiving TILs only (day 22), and one animal from groups treated with Ad5/3-E2F-d24-hTNF-a (day 29) and Ad5/3-E2F-d24-hIL-2 (day 29). Small
amounts of viral DNA were detectable also in non-injected tumors on day 16 (C). There were no differences between the injected and non-injected tumor sizes on day 33 (D).
The graphs show mean plus SEM. Statistical differences were evaluated with mixed model analysis; ****p < 0.0001; ***p < 0.001; **p < 0.01; *p < 0.05.
Molecular Therapy: OncolyticsTo decrease the toxicity and increase the efﬁcacy of T cell-related im-
munotherapies, such as adoptive cell therapy and checkpoint inhibi-
tors, we have developed an oncolytic adenovirus coding for human
tumor necrosis factor alpha (TNF-a) and interleukin-2 (IL-2)
(Ad5/3-E2F-d24-hTNF-a-internal ribosome entry site [IRES]-
hIL-2, a.k.a. TILT-123).17–19 We hypothesized that oncolytic adeno-
virus replication accompanied by IL-2 and TNF-a production from
tumor cells induces immunological effects that are powerful not
only locally but also system-wide. Because we have seen Ad5/
3-E2F-d24-hTNF-a-IRES-hIL-2 inducing positive changes locally
in the tumor-inﬁltrating immune cell milieu, as well as on a systemic
level,17 we studied whether a local treatment would be able to generate
an abscopal effect on distant tumors and the mechanisms behind it.
RESULTS
Cytokine-Armed Oncolytic Adenoviruses Induce Systemic
Antitumor Responses
The systemic effects of a local treatment with oncolytic Ad5/3-E2F-
d24-hTNF-a-IRES-hIL-2 were studied in Syrian hamsters that are
semi-permissive for human adenovirus replication.20 In addition,
certain human cytokines, including TNF-a and IL-2, are bioactive
in hamsters.17,20 Because this virus was developed to enable T cell110 Molecular Therapy: Oncolytics Vol. 11 December 2018therapies, the experimental settings included a treatment with tu-
mor-inﬁltrating lymphocyte (TIL) graft. We observed tumor growth
reduction in both injected and non-injected tumors without differ-
ences in tumor sizes between these tumors (Figures 1A, 1B, and 1D).
The arming devices resulted in a beneﬁt in tumor control over the
respective unarmed virus. With regard to injected tumors, the best
groups were Ad5/3-E2F-d24-hTNF-a and Ad5/3-E2F-d24-hTNF-
a-IRES-hIL-2 (p = 0.002 and p = 0.0034 compared with TILs alone,
respectively; p = 0.002 and p = 0.01 compared with mock). Regarding
non-injected tumors, all armed viruses had enhanced antitumor
efﬁcacy at the non-injected site, unlike the unarmed virus, when
compared with mock and TILs alone (TIL versus TIL + TNF-a:
p = 0.001; TIL versus TIL + IL-2: p = 0.000427; TIL versus TIL +
TNF-a-IL-2: p = 0.00007; mock versus TIL + TNF-a: p = 0.011;
mock versus TIL + IL-2: p = 0.022; mock versus TIL + TNF-a-IL-2:
p = 0.006).
The viruses were present in injected tumors at high levels on day 16,
8 days after the last intratumoral injection. The highest values were
observed in the group treated with the unarmed virus (Figure 1C).
Viral DNA levels were low in non-injected tumors and normal tissues
Figure 2. Replication-Incompetent Virus Induces Growth Control Also in the Non-injected Tumor at an Early Time Point
The sizes of injected (A and C) and non-injected (B and D) B16-OVA tumors in mice on day 8 (n = 3–8) without T cell transfer (A and B) or with OT-I cells (C and D) were
compared with averagemock tumor size on the same time point. Similar results were obtained for injected (E) and non-injected (F) tumorswhen the experiment was repeated.
Viral DNA was detected only in the injected tumors (G). The bars show mean plus SEM. Statistical significance was evaluated with 2-way ANOVA: ****p < 0.0001;
***p < 0.001; *p < 0.05.
www.moleculartherapy.org(Figures 1C and S1A). The highest individual values were detected in
spleen, liver, and lung, but there were no differences in biodistribution
between viruses or organs.
After treatments, animals were monitored and sacriﬁced according
to animal regulations (tumor size reaching 20 mm). The group
treated with the double-armed virus had the best survival (p =
0.03 and p = 0.0159 compared with mock and TILs alone, respec-
tively), whereas TILs alone had a minimal effect on survival
(Figure S1B).
Arming with TNF-a and IL-2 Results in an Abscopal Effect Even
without Oncolysis
Next, we sought to dissect the effect of the transgenes from the effects
of oncolysis. This could be achieved by using replication-incompetent
adenoviruses with murine cytokines in immunocompetent mice
bearing B16 melanoma tumors expressing chicken ovalbumin
(OVA). By day eight, an early time point, a difference in tumor size
could be seen in both injected and non-injected tumors (Figures 2A
and 2B). The tumors injected with IL-2- and TNF-a-armed viruses
were about 70% smaller than the PBS-injected vehicle control tumors
(p < 0.0001). The control virus Ad5-Luc1, which lacks an immuno-
logically active transgene, had a minor yet statistically signiﬁcant
effect (p = 0.0004).Regarding non-injected tumors, the armed viruses were the only ones
able to induce tumor growth control (vehicle versus Ad5-CMV-
mTNF-a: p = 0.0162; vehicle versus Ad5-CMV-mIL-2: p = 0.0475;
vehicle versus Ad5-CMV-mTNF-a/mIL-2: p = 0.0212). The best
tumor control was induced by the combination of the cytokines,
mean tumor size being half of the size of the vehicle tumors. The addi-
tion of OVA-speciﬁc OT-I T cells resulted in similar outcomes but did
not enhance tumor growth control at this early time point (Figures 2C
and 2D).
The experiment was repeated with themost relevant treatments: OT-I
T cells with vehicle control, control virus Ad5-Luc1, and Ad5-CMV-
mTNF-a/mIL-2. Tumor growth was followed for 6 days. The treat-
ment did not inﬂuence the growth of injected tumors, but the animals
treated with cytokine-armed viruses clearly showed a delay in non-
injected tumor growth as compared with vehicle treatment (p =
0.04; Figures 2E and 2F). Of note, the effect was not due to virus
spread because viral genomes at the non-injected tumors were unde-
tectable (Figure 2G). Thus, the viral transduction of distant tumors
seems to require oncolysis and subsequent shedding of the virus
from tumors into blood.
Day eight tumors were collected and analyzed for intratumoral im-
mune cell populations. The percentage of natural killer (NK) cellsMolecular Therapy: Oncolytics Vol. 11 December 2018 111
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population) was elevated in both injected and non-injected tumors
following treatment with cytokine-coding viruses (Figure 3A). In
addition, the cytokine combination was able to increase the levels
of CD11c- and CD86-positive dendritic cells in treated tumors, and
the trend was similar in non-injected tumors (Figure 3B). Moreover,
there was a positive correlation between the presence of NK cells and
dendritic cells (Figures S2A and S2B).
An increase of F4/80 and CD11b-positive macrophages was observed
in both tumors (Figure 3C). Interestingly, the portion of immunosup-
pressive M2-like macrophages (differentiated by CD206 expression)
was decreased when tumors received cytokine-coding viruses (Fig-
ure 3D). Again, a similar, yet not signiﬁcant, trend was seen in
non-injected tumors. Out of other markers for immunosuppression,
the treatments did not affect the expression of TGF-b or FoxP3 (Fig-
ures S2C and S2D). No major differences were observed between the
groups regarding melanoma-speciﬁc (OVA, Trp2, and gp100) CD8-
positive T cells (Figure 3E). The presence of any of the immune cell
populations studied here did not correlate with tumor volumes (Fig-
ures S2E–S2J).
Armed Adenovirus Induces the T Cell Graft Trafficking into Both
Injected and Non-injected Tumors
Because the oncolytic virus was able to travel to the non-injected
tumors, we wanted to study whether the virus induces TIL graft traf-
ﬁcking into both injected and non-injected tumors. Distribution and
tumor accumulation of the radiolabeled cells (111In-oxine) were
determined by single-photon emission computed tomography/
computed tomography (SPECT/CT) imaging at 48, 72, and 96 hr after
administration (Figures 4A and 4B). A trend of increased trafﬁcking
into both injected and non-injected tumors was observed in animals
treated with Ad5/3-E2F-d24-hTNF-a-IRES-hIL-2 compared with the
unarmed virus and the vehicle control (Figure 4C). In addition, the
cells seemed to be more persistent in the tumors when the animals
were treated with the cytokine-armed virus: there was no decrease
over time in the injected or non-injected tumors, whereas in the
vehicle and unarmed virus control groups the signal decreased over
time.
To estimate the effect of the cytokines on T cell graft trafﬁcking, ﬂuo-
rescently labeled OT-I T cells were administered to animals receiving
vehicle, Ad5-Luc1 control virus, or Ad5-CMV-mTNF-a/IL-2 into
one of the two tumors. Five days later, the tumors were collected
and the presence of transferred T cells detected with ﬂow cytometry.
Even in the absence of oncolysis, treatment of one tumor was able to
induce OT-I cell trafﬁcking into both injected and non-injectedFigure 3. Treatment with Armed Viruses Induces Positive Changes in Immune
Tumor samples were collected on day 8, and the presence of natural killer cells (A), matu
detected with flow cytometry. Melanoma-specific T cells were detected with pentame
Statistical differences were analyzed against correspondingmock tumor. The bars show
controls, and gray bars treatment groups with armed viruses. Unpaired t test was per
*p < 0.05.tumors (Figure 4D). The transferred T cells did not ﬁnd their way
into the tumors when the animals were treated with vehicle control,
and only a low signal was detected in non-injected tumors in animals
receiving the control virus. There were no statistically signiﬁcant
differences between the injected and non-injected tumors.
Oncolytic Adenovirus Induces the Expression of
Immunologically Relevant Genes in Injected and Non-injected
Tumors
In order to uncover the mechanisms of action underlying the sys-
temic effects and the trafﬁcking of adoptively transferred cell graft,
we analyzed the gene expression proﬁles of injected and non-in-
jected tumors in hamsters receiving TIL therapy. In the vehicle
group, PBS injection induced immune reactions by the upregula-
tion of the genes related to humoral immune responses, chemo-
kine and cytokine production, inﬂammatory responses, and
complement activation, among others (Table S1). In addition,
the PBS injection downregulated genes related to cytoskeleton
organization and other ﬁlament-related processes. To allow for
the effects of the needle puncture and vehicle injection, we
analyzed treatment group expression levels against corresponding
vehicle group tumors.
Over 2-fold upregulation was observed for 445 genes in injected tu-
mors and for 165 genes in non-injected tumors (Figures S3 and 5).
The number of downregulated genes was 45 and 70 in injected and
non-injected tumors, respectively (Figures S3 and 6). TIL treatment
without viruses induced the expression of chemokines (Ccl4, Ccl7,
Ccl11), but also immune checkpoint molecules Pdl1 (or Cd274) in
the PBS-injected tumors and Lag3 in the non-injected tumors. In
addition, we saw upregulation of a variety of lymphocyte-related
genes (Sash3, Fgl2, Txk, Gzmk, Bst1, Pik3ap1, Pik3cd, Prkcb, Nkg7,
Spn), T cell activators (Prkcq, Tagap) and inhibitors (Ptprc, Ptpn22),
dendritic cell marker Itgax (or Cd11c), genes promoting cytokine
production (Themis2, Fgr, Trem1), and Rnf144b, whose product
functions in major histocompatibility complex (MHC) class I antigen
processing and presentation (Figures 5 and S5).
Virus Injection Induces the Upregulation of Genes Related to
Both Innate and Adaptive Immunity
Out of immunologically relevant genes, injection with either virus
induced the expression of macrophage marker Scara5, chemokine
gene Cxcl12, lymphocyte differentiation marker Nt5e, and two genes,
Retnla and Retnlb, related to T cell and dendritic cell recruitment,
respectively. In addition, we saw upregulation of T cell inhibitor
Ido1 in non-injected tumors in the group treated with the unarmed
virus and TILs. In addition, as seen in mice, virus injection wasCells in the Tumor Microenvironment
re dendritic cells (B), macrophages (C), and M2-like macrophages (D) in tumors was
rs and the results with OVA+, Trp2+, and gp100+ cells pooled into one graph (E).
mean plus SEM. Black bar indicates mock control, white bars unarmed virus or OT-I
formed to analyze statistical differences; ****p < 0.0001; ***p < 0.001; **p < 0.01;
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Figure 4. Armed Virus Induces TIL and TCR Graft
Trafficking to and Persistence in Both Tumors
TILs were labeled with radioactive indium, and the
trafficking into (A) injected and (B) non-injected tumors
was followed with SPECT/CT imaging over time. On
day 0, the hamsters received the labeled TILs intraperi-
toneally and viruses or PBS control intratumorally into
one of the two tumors (n = 2/group). The difference
between the groups was most prominent 96 hr after the
administration of the cells (C). TCR-modified OT-I cells
were labeled with fluorescent-labeled nanoparticles,
and their presence in injected and non-injected
tumors was investigated after 5 days (n = 6) (D). Tumors
injected with viruses coding for TNF-a and IL-2 had
significantly higher numbers of infused OT-I cells
compared with vehicle-treated tumors (Kruskal-Wallis
test, *p < 0.05).
Molecular Therapy: Oncolyticsable to upregulate NK cell activationmarkers and dendritic cell differ-
entiation (Figure S5).
The unarmed virus induced the upregulation of the highest number
of genes. Among the genes upregulated in the unarmed group, there
were several T cell markers (Itm2a, Prkcq,Dpp4, Aplnr), B cell-related
genes (Jchain, Ebf1, Fgd2, Mzb1), chemokines and their receptors
(Ccl21, Ackr1, Ccr5, Cmklr1, Cxcl14), complement system-related
genes (C1s, C1r, C3ar1 C4, C6, C7), and antigen presentation-related
genes (B2m, Tap1, Tap2, Tapbp; Figure S4). Interestingly, Ad5/3-E2F-
d24 also upregulated genes that are required for lymphocyte migra-
tion and invasion, such as Vcam1, Pecam1, and Esam, in addition
to CD34 and Sell, coding for the binding partner of CD34 on
T cells, L-selectin. Another interesting detail unique to the unarmed
virus was the upregulation of genes related to viral processes, for
example, antiviral Rsad2 (Figure S5). In addition, we saw downregu-
lation of inﬂammation-related genes such as S100a9, S100a8, Orm1,
Ltb (or Tnfc), and Gc (Figures 6 and S6).
Armed Adenovirus Induces Chemokine Expression in Both
Injected and Non-injected Tumors
Tumors injected with armed virus showed unique upregulation
of cytokine genes Csf3 and Il1b. In addition, we saw an upregula-114 Molecular Therapy: Oncolytics Vol. 11 December 2018tion of macrophage-related gene Marco, and
Ackr3 coding for an atypical chemokine recep-
tor. In the same group, the non-injected tu-
mors showed upregulation of immunoglobulin
lambda- and kappa-like genes. When expanding
the observations to all signiﬁcantly differentially
expressed genes present both in injected and
non-injected tumors uniquely in this group,
we observed upregulation of Cxcl5 coding for
TNF-a-inducible chemokine and Rnase2 that
attracts dendritic cells (Table S2). Furthermore,
we saw upregulation of the following genes
related to immune reactions: Ier3 that hasfunctions in TNF-a-stimulated apoptosis and T cell apoptosis
inhibition; Lrmp, whose protein product delivers peptides to
MHC class I molecules; B cell regulator Rgs13; and Sult1e1 that
is involved in inﬂammatory-response regulation. By contrast, im-
mune-reaction-related genes that were downregulated in this group
in both tumors were Jak3 (mediates IL-2R signaling in T cells and
NK cells) and three genes coding for parts of MHC class II complex
(Table S2).
Because the double-armed virus had more prominent antitumor ab-
scopal effects on the non-injected tumors in comparison to the same
virus without arming devices, it was of interest to study those genes
that changed only in non-injected tumors, and only when the dou-
ble-armed virus was used for injection of the other tumor. In theory,
this could allow dissection of the abscopal effects of oncolysis from
the effects of the transgenes. However, only a few such genes were
identiﬁed (upregulation of LOC101839749 and LOC101842437,
annotated as immunoglobulin lambda-1 light chain-like and immu-
noglobulin kappa variable 4-1-like, respectively, and downregulation
of Ca3, Mylpf, Ckm, and Hspb1), but they are currently of unknown
signiﬁcance in the context of immunotherapy. Further cell biology
research could eventually help understand the role of these transcripts
in our ﬁndings.
(legend on next page)
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Cytokines, such as TNF-a and IL-2, are potent inducers of antitumor
immunity. TNF-a has both direct and indirect effects on cancer cells
by inducing necrosis and apoptosis, but also inducing immunologic
reactions via acute inﬂammation.21 Recombinant TNF-a is routinely
used in isolated limb perfusion of, for example, sarcoma and mela-
noma, but it is too toxic to be used systemically.22,23 With adenoviral
delivery, high local concentration of TNF-a and IL-2 is achievable
without signiﬁcant systemic exposure.17,18 IL-2 functions as a T cell
propagator and activator, and it is used as a treatment for melanoma
and renal cell carcinoma. IL-2 is also included in many adoptive cell
therapy trials, especially in TIL therapy and in many solid tumor trials
with chimeric antigen receptor T cells (CART) or with receptor-
modiﬁed T cells (TCR).24–26 Again, vectored delivery can achieve
the beneﬁcial effects of IL-2 without systemic toxicity.13 Here, we in-
serted TNF-a and IL-2 into an oncolytic adenovirus and studied the
systemic antitumor effects of Ad5/3-E2F-d24-hTNF-a-IRES-hIL-2
with adoptive T cell transfer.
Oncolytic adenoviruses whose capsid is a chimera between serotype 5
and serotype 3 appear useful with regard to systemic delivery. In line
with the results obtained in this study, we have previously shown in
both laboratory animals and humans that virus administered intratu-
morally or intravenously can transduce distant metastases.11,27 It has
even been possible to grow out the treatment virus from non-injected
brain metastases of a cancer patient.11 Injected and non-injected tu-
mors were transduced to the same degree in patients. Thus, the 5/3
chimeric platform is appealing for achieving systemic effects also
through viral transduction, in addition to immunological effects.
Consistent with previous results, the oncolytic virus studied here could
be detected in both injected and non-injected tumors. The virus spread
was linked to replication, because the replication-incompetent viruses
were not found in non-injected tumors. Oncolytic virus levels were
higher in injected tumors than in non-injected tumors, but the pres-
ence in non-injected tumors in immune-competent hosts constitutes
an important proof-of-concept. Moreover, the level of unarmed virus
in injected tumors was higher than that of armed viruses, suggesting
more extensive immunogenicity of the armed viruses. Because the vi-
ruses were found in non-injected tumors, it was not surprising to ﬁnd
them also in normal tissues. The selectivity of the virus, however, is not
at the level of entry, but on the level of replication.28 Because the virus
does not replicate in normal cells, these cells are not damaged and no
adverse events are seen.17 In fact, higherDNA copy number can some-
times be seen in normal human tissues than in tumors.11
In contrast with oncolytic adenovirus, the ﬁrst oncolytic virus
approved by authorities in the United States and European Union
(EU), T-Vec, has not been detected from non-injected tumors inFigure 5. List of Genes Upregulated over 2-Fold Compared with Correspondin
Genes in cluster 1 are upregulated only in non-injected tumors, genes in cluster 2 are u
injection, genes in cluster 4 are upregulated with either virus, genes in cluster 5 are upreg
injection. Black box indicates over 2-fold upregulation.
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responses in distant tumors, even though at a lower level.6,7 In the
phase 3 OPTIM trial, T-Vec resulted in a 26% response rate in in-
jected tumors and 15% in non-injected visceral metastases.6 Because
our approach induced similar efﬁcacy in injected and in non-injected
tumors, one can speculate that overall clinical beneﬁts could be more
pronounced if the virus is capable of transducing non-injected tu-
mors. Thus, there is a major difference between oncolytic herpes
type 1 and oncolytic 5/3 chimeric adenovirus, and this difference is
potentially very important clinically. The former can produce sys-
temic effects through the immune system, whereas the latter can
achieve body-wide effects though two mechanisms: (1) viral dissem-
ination through the vasculature, transduction of distant tumors fol-
lowed by transgene expression, and oncolysis; and (2) systemic
immunological effects. Considering there are several oncolytic viruses
in development, it is clear that they are not all alike with regard to the
mechanisms of action and systemic efﬁcacy.
As a result of virus spread into non-injected tumors, there were no
signiﬁcant differences between the sizes of injected and non-injected
tumors in this study. Moreover, cytokine-armed viruses inﬂuenced
circulating T cell graft seen as increased trafﬁcking into distant
tumors, both with oncolytic and replication-incompetent viruses.
The experiment with replication-incompetent viruses without T cell
therapy highlighted the importance of the transgenes in inducing
the systemic antitumor effects. Even in the absence of oncolysis, the
replication-incompetent viruses were able to inhibit the growth of
the non-injected tumors when armed with TNF-a and IL-2. More-
over, with oncolytic viruses, the unarmed virus was not able to induce
as strong antitumor effects as the armed viruses in the non-injected
tumors despite higher copy number. The results are in line with
our previous results with the same constructs: TNF-a and IL-2 are
necessary for enabling curative treatment with TIL therapy and
inducing immunological memory against tumor rechallenge.17
Here, the two different animal models, hamsters and mice, both sug-
gest that the transgenes have an importance in inducing systemic
antitumor effects.
Due to limited availability of hamster-speciﬁc or cross-reactive re-
agents, a mouse model provided us a means to study immune cell
compartments in tumors, having the focus on innate immunity.
Interestingly, treating just one tumor induced immune cell inﬁltration
also into the non-injected tumor. Moreover, the presence of immune
cells in tumors did not correlate with tumor sizes, suggesting that the
treatment inﬂuences tumor microenvironment regardless of the vol-
ume. The clearest difference was seen with NK cells that are known to
attack cells with low MHC class I expression, such as B16-OVA.30,31
The presence of any virus induced NK levels in the injected tumors,
but an arming device was required for NK cell induction in theg Mock Group
pregulated in both tumors, genes in cluster 3 are upregulated with Ad5/3-E2F-d24
ulated with Ad5/3-E2F-d24-hTNF-a-IRES-hIL-2 only, and genes in cluster 6 with any
Figure 6. List of Genes Downregulated over 2-Fold Compared with
Corresponding Mock Group
Genes in cluster 1 are downregulated in TIL group, genes in cluster 2 are down-
regulated with a virus injection, and genes in cluster 3 are downregulated only in
non-injected tumors. Black box indicates over 2-fold downregulation.
www.moleculartherapy.orgnon-injected tumor. Interestingly, also Balasa et al.32 reported the
importance of the combination of IL-2 and TNF-a with regard to
NK activation.
In addition to NK cells, IL-2 stimulated the presence of dendritic cells
expressing the maturation marker CD86. Moreover, the presence of
mature dendritic cells positively correlated with higher numbers of
NK cells in the tumor. Crosstalk between NK cells and dendritic cells
has an interesting role in both innate and adaptive immunity. NK cells
promote tumor antigen presentation by dendritic cells, but at the
same time, CD11c-positive dendritic cells are required for NK cell
priming.33,34 Moreover, NK cells induce dendritic cell maturation
both via cell-cell contacts and via secretion of TNF-a and interferon
gamma.35 NK cells additionally secrete chemokines, such as MIP-1a,
MIP-1b, and RANTES, which attract dendritic cells.36
In addition to inducing dendritic cell maturation, TNF-a is capable of
suppressing the M2 macrophage phenotype.37 Immunosuppressive
M2-like macrophages are known to associate with poor survival in
cancer patients, and cancer cells appear to attempt to drive macro-
phage differentiation toward this phenotype.38,39 We saw, however,
a relative decrease in this subtype of macrophages when tumors
were injected with armed viruses even though the overall macrophage
percentage was increased in both tumors. The effect was most notice-
able with TNF-a-coding virus. A similar trend was seen in gene
expression proﬁles in hamster tumors where 12 out of 19 genes
speciﬁc for M1 macrophages according to Kratochvill et al.37 were
upregulated in tumors treated with Ad5/3-E2F-d24-hTNF-a-IRES-
hIL-2. Likewise, the expression of 13 out of 20 genes that are linked
to M2 phenotype was absent in the tumors.
When interpreting gene expression data, it is important to extract
the effects derived from the delivery of the drug. We have previously
observed that injection with saline causes immunological reactions
in tumors.40 This phenomenon was conﬁrmed in our observations
with the upregulation of immune-reaction-related genes caused
by injection of PBS. To control the effect of PBS injection, we
compared the gene expression proﬁles of the virus-injected tumors
with the saline-injected tumors and the non-injected tumors with
the non-injected tumors in the vehicle group. Most changes in
gene expression proﬁle occurred in the group treated with the
unarmed virus. Because this virus causes fewer immune responses
toward tumor cells that allow replication, oncolysis is more promi-
nent, and therefore the majority of the expression changes seen are
due to this phenomenon. For example, the virus upregulated many
of the complement system components, suggesting that the un-
armed virus might have induced more antiviral immune responses
than the armed virus.Molecular Therapy: Oncolytics Vol. 11 December 2018 117
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of the transferred cells in both injected and non-injected tumors,
regardless of oncolysis. Previously, increased chemokine expression
in the tumors treated with replication-incompetent adenoviruses
armed with TNF-a and IL-2 was linked to increased T cell trafﬁcking
in mice.18 Here, we studied the effect of oncolytic viruses on chemo-
tactic genes and genes promoting leukocyte proliferation and survival
in both injected and non-injected tumors. Interestingly, many of
these, such as Cxcl5, Rnase2, and Ier3, were uniquely upregulated in
the group treated with Ad5/3-E2F-d24-hTNF-a-IRES-hIL-2.
In addition to chemokines, we saw upregulation of a set of genes
related to different immune cell compartments, invasion of T cells
through the vessels, and antigen presentation. Recently, Patel
et al.41 reported extensive analysis of genes important for responses
to immunotherapy in cancer. Interestingly, the same genes related
to MHC class I antigen processing and presentation (B2m, Tap1,
Tap2, and Tapbp) were upregulated in tumors injected with Ad5/
3-E2F-d24 and in animals treated with TILs only. Moreover, they
discovered that loss-of-function mutations inAplnr, coding for apelin
receptor, reduce the effectiveness of T cell therapies, including anti-
CTLA4 blockade. Of note, in our dataset, Aplnr was upregulated in
all the injected tumors and in the non-injected tumors in the group
that received Ad5/3-E2F-d24. Of course, the efﬁcacy of an immuno-
therapeutic does not depend on the expression of a single gene, but is
a matter of inducing the right set of genes. Nevertheless, the correla-
tion of our data with Patel’s data is tantalizing, and because they used
different methodology and made the observations from human data,
the identiﬁed genes seem indeed relevant for cellular immunotherapy.
To conclude, our study demonstrates systemic effects induced by local
injection of Ad5/3-E2F-d24-hTNF-a-IRES-hIL-2. The virus was able
to spread to non-injected tumors, while the experiments with replica-
tion-incompetent viruses pointed out the importance of the arming
device. Together, the oncolytic replication and the arming devices
induced upregulation of genes essential for successful immuno-
therapy. Thus, an abscopal effect was seen and it was caused by two
synergistic phenomena: (1) viral dissemination through the blood-
stream into distant tumors, followed by oncolysis, and (2) systemic
immune response. Taken together with previous reports, the ﬁndings
presented here underline the rationale for using Ad5/3-E2F-d24-
hTNF-a-IRES-hIL-2 as an enabler of T cell therapies and checkpoint
inhibitors. A clinical trial, where the virus is used in patients receiving
adoptive TIL therapy, is in progress.
MATERIALS AND METHODS
Cell Lines and Viruses
All cells lines were maintained under recommended conditions and
tested to be pathogen-free. In mouse experiments, we used mouse
melanoma cell line B16-OVA, a kind gift from Prof. Richard Vile
(Mayo Clinic, Rochester, MN, USA), and replication-deﬁcient adeno-
viruses Ad5-CMV-mIL-2, Ad5-CMV-mTNF-a, and Ad5-Luc1.18,42
Oncolytic adenoviruses Ad5/3-E2F-d24, Ad5/3-E2F-d24-hTNF-a,
Ad5/3-E2F-d24-hIL-2, and Ad5/3-E2F-d24-hTNF-a-IRES-IL-217118 Molecular Therapy: Oncolytics Vol. 11 December 2018were studied with hamster pancreatic cancer cell line HapT1
(DSMZ, Braunschweig, Germany).
Hamster Experiments
Oncolytic adenoviruses armed with human TNF-a and IL-2 were
studied in Syrian hamsters (Envigo). 4  106 HapT1 cells were im-
planted on both ﬂanks of the animals and allowed to develop for
7 days. Tumors were treated with 1  108 viral particles (VPs) intra-
tumorally once a week and once with 5  107 HapT1-derived TILs
administered intraperitoneally. As a control, one of the two tumors
in the TIL group was treated with PBS, whereas the mock tumors
were left untreated. The extraction of TILs is described previ-
ously.17,43 Four animals per group were sacriﬁced after two virus
treatments on day 16, and tumors, heart, lung, liver, spleen, and kid-
ney were collected from each animal to detect biodistribution of the
virus with qPCR. Tumor sizes on the rest of the animals (5–6 per
group) were followed for 122 days.
Mouse Experiments
The Experimental Animal Committee of the University of Helsinki
and the Provincial Government of Southern Finland approved the
animal experiments performed in this study. To investigate the
effects of the adenovirally delivered transgenes, two B16-OVA tumors
(2.5 105 cells each) were implanted into the ﬂanks of C57BL/6 mice
(Envigo, Cambridgeshire, UK).When the tumor size reached approx-
imately 5 mm 10 days after the implantation, the animals were ran-
domized into groups of 8–11 and treated intratumorally on days 1
and 4 with 1  109 VPs for single viruses or 0.5  109 VPs each
when the virus coding for mIL-2 and mTNF-a were combined. The
vehicle control group received PBS. CD8-enriched OVA-speciﬁc
OT-I cells were processed as described previously40 and administered
1.4  106 cells per animal intraperitoneally on day 1. The animals
were sacriﬁced a week after the treatments, and tumors were collected
for detecting the spread of the virus and the immune cell contents.
To investigate OT-I cell trafﬁcking in mice, we labeled the cells with
Qtracker 565 Cell Labeling Kit (Thermo Fisher Scientiﬁc, Waltham,
MA, USA). The animals received intraperitoneally 7.6  105 cells,
out of which 14% showed a positive ﬂuorescent signal. One of the
two B16-OVA tumors was injected with 50 mL of PBS, 1  109 VPs
of Ad5-Luc1 or Ad5-CMV-mTNF-a and Ad5-CMV-mIL-2 in a
one-to-one ratio on days 1 and 3. Tumors were collected on day 6
and analyzed for ﬂuorescein isothiocyanate (FITC)+ CD8+ cells, rep-
resenting the transferred OT-I cells.
SPECT/CT Imaging
TILs were labeled with 111In-oxine and administered intraperitone-
ally into Syrian hamsters (5  107 cells, 5.82 ± 0.73 MBq) bearing
two HapT1 tumors (n = 4/group). One of the two tumors received
1  108 VPs of Ad5/3-E2F-d24, Ad5/3-E2F-d24-TNF-a-IRES-IL-2,
or 50 mL of PBS as a control on day 0, and the animals were imaged
with NanoScan SPECT/CT (Mediso, Budapest, Hungary) at 48, 72,
and 96 hr after the administration of the cells. The results are reported
as standardized uptake values (SUVs), which were calculated using
www.moleculartherapy.orgthe average radioactivity concentration in the whole tumor normal-
ized with the injected radioactivity dose and the animal weight. The
tumors were delineated by using the co-registered CT images.
Gene Expression Profiling
To dissect the mechanisms of action on the gene expression level, we
performed mRNA sequencing. Two of four subcutaneously estab-
lished HapT1 tumors received virus and TIL treatments as described
above. On day 10, 2 days after the last treatment, tumors were
collected and stored in RNAlater (AM7020; Life Technologies,
Thermo Fisher Scientiﬁc) before extracting RNA with RNeasy Mini
Kit (74104; QIAGEN, Valencia, CA, USA). The library for sequencing
was prepared with NEBNext Ultra Directional RNA Library Prep Kit
3 (E7420S; New England Biolabs, Ipswich,MA, USA) before perform-
ing single-end Illumina NextSeq High Output 1  75 bp sequencing
(FC-404-2005; Illumina, San Diego, CA, USA).
The quality of the acquired data was analyzed with FastQ and sum-
marized with MultiQC.45,46 Light quality trimming was performed
with Trimmomatic.47 The sample reads were aligned and annotated
against RefSeq GCF_000349665.1_MesAur1.0_genomic reference
and quantiﬁed with featureCounts.48 Expression proﬁles of injected
and non-injected tumors in the treatment groups were compared
with corresponding tumors in the vehicle group, and the statistics
for differentially expressed genes were calculated with DESeq2.49
For each set of differentially expressed genes, obtained by comparing
the treated group against the corresponding mock group (fold change
> 1, p < 0.05), gene ontology analysis was performed against human
orthologs with the WebGestalt toolkit.50 The human orthologs were
retrieved from the NCBI database.51,52
In addition, the expression of TGF-b and FoxP3 were assessed from
the RNA samples by qRT-PCR. The RNA was transcribed to cDNA
with High-Capacity cDNAReverse Transcription Kit (Thermo Fisher
Scientiﬁc) according to manufacturer’s instructions. The primer and
probe sequences were adopted from Zivcec et al.,53 and the results
were normalized against GAPDH housekeeping gene as previously
described.44
Flow Cytometry
Dendritic cells, macrophages, NK cells, and melanoma marker (Trp2,
gp100, and OVA)-speciﬁc T cells were detected from mouse tumor
samples with ﬂow cytometry as described by Tähtinen et al.54
Virus Spread into Organs and Untreated Tumors
DNA was extracted from 25-mg tissue samples with QIAmp DNA
Mini Kit (51326; QIAGEN), and the QIAcube machine according
to the manufacturer’s protocol. Adenoviral E4 was detected by
qPCR as described earlier and normalized against hamster GAPDH
or mouse b-actin gene expression.42,44
Statistics
Tumor growth curves were analyzed with mixed model analysis in
IBM SPSS Statistics version 22.0.0.1 (IBM, Armonk, NY, USA). Othercalculations were made with GraphPad Prism 7.03 (La Jolla, CA,
USA). The survival beneﬁt was evaluated with log rank test, and the
other results were analyzed with ANOVA, Kruskal-Wallis test, or
unpaired t test. All tests were performed as two-sided.
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